Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Signs Deal for A$24M Equity Placement Facility

NEW YORK (GenomeWeb) – Genetic Technologies said today that it has entered into a A$24 million (US$19.4 million) standby equity placement facility agreement with investment fund Kentgrove Capital Growth Fund. 

Funds from the facility will be used to grow Genetic Technologies' lead breast cancer test, BrevaGenplus, and for general working capital. 

Under the terms of the deal, Kentgrove will provide the Australian molecular diagnostics firm with up to A$24 million of equity capital via placements over the next 24 months. The facility expires on Jan. 21, 2017. 

Genetic Technologies Chairman Malcolm Brandon said in a statement that the facility will allow the firm to continue establishing and expanding the market for the BrevaGenplus test in theUS. "Our sales and marketing infrastructure and strategy is now focused on engaging with healthcare professionals in comprehensive breast and imaging centers where we can achieve the highest throughput rates as the centers adopt this test as an important part of their breast cancer risk management programs," he said. 

BrevaGenplus is the next-generation of the firm's breast cancer test and was launched in late 2014. Late last month, Genetic Technologies said that it raised A$258,000 in a share purchase plan. 

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.